DEVICE AND METHOD FOR DELIVERING THERAPEUTIC SUBSTANCES TO THE MAXILLARY SINUS OF A PATIENT

• US 20110151393A1
• Filed: 12/14/2010
• Published: 06/23/2011
• Est. Priority Date: 12/18/2009
• Status: Active Grant

• Current Assignee: Healthpartners Research Foundation (Health Partners Institute For Education & Research)
• Original Assignee: Healthpartners Research Foundation (Health Partners Institute For Education & Research)
• Inventors: Frey, William H. II, Johnson, Neil J.
• Granted Patent: US 8,622,993 B2
• Time in Patent Office: Days
• US Class Current: 433/24
• CPC Class Codes: A61B 17/24 for use in the oral cavity, larynx, bronchial passages or nose for medical inspection of cavities or tubes in the body A61B1/00; Tongue scrapers
• CPC Class Codes: A61C 19/06 Implements for therapeutic treatment radiation therapy A61N5/00
• CPC Class Codes: A61C 19/08 combined with anaesthetising implements dental hypodermic syringes A61M5/00
• CPC Class Codes: A61C 5/40 Implements for surgical treatment of the roots or nerves of the teeth; Nerve needles; Methods or instruments for medication of the roots
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008

Abstract

The present invention is directed to devices and methods for administering at least one effective dose of at least one therapeutic substance to at least one of the maxillary sinuses of a patient in need thereof. Alternate embodiments may comprise administration of the at least one effective dose of at least one therapeutic substance to both maxillary sinuses, where the administered therapeutic substance(s) are either the same or differ from sinus to sinus. Still further alternative embodiments may comprise more than an initial effective dose administered to a patient'"'"'s maxillary sinus(es), so that the therapeutic substance may be delivered over time, thereby requiring a larger dose be deposited within at least one of the maxillary sinuses so that the maxillary sinus(es) serve as a therapeutic substance depot for long-term release to the target structure(s).

Claims

1. A method to treat a patient'"'"'s anatomical structures innervated by the trigeminal nerve and in need thereof, comprising:

providing a delivery device adapted for insertion into the patient'"'"'s nasal cavity and operative connection with one of the patient'"'"'s maxillary sinus opening;

inserting the delivery device into the patient'"'"'s nasal cavity until it reaches at least one of the patient'"'"'s maxillary sinus openings;

administering at least one effective dose of at least one therapeutic compound selected from the group consisting of lidocaine, tetracaine, articaine, marcaine, and benzocaine via the delivery device through the at least one maxillary sinus opening, wherein the at least one effective dose comprises a volume of at least 0.3 milliliter;

depositing the at least one effective dose within the maxillary sinus; and

treating the structures innervated by the trigeminal nerve with the at least one therapeutic compound.

2. The method of claim 1, further comprising treating structures innervated by the trigeminal nerve and selected from the group consisting of:

maxillary teeth, the nerve endings in the maxillary teeth, gums;

the nerve endings in the gums, vasculature innervated by the trigeminal nerve, temporomandibular joint, masseter muscle, lacrimal glands, parotid glands, submandibular glands, sublingual glands, meninges, skin of the forehead, tongue, maxilla, mandible, incisive nerve, greater palatine nerve, and the anterior, middle and posterior alveolar nerves.

3. The method of claim 1, further comprising treating the structures before, during and/or after a dental procedure.

4. The method of claim 1, further comprising administering at least one therapeutic substance from the group consisting of an analgesic, an anesthetic, an anti-inflammatory compound, an antioxidant compound, an antiviral, an antibiotic, and bone morphogenic protein (BMP).

5. A method to treat a patient'"'"'s periodontal disease and the symptomatic anatomical structures innervated by the trigeminal nerve and in need thereof, comprising:

providing a delivery device adapted for insertion into the patient'"'"'s nasal cavity and operative connection with one of the patient'"'"'s maxillary sinus opening;

inserting the delivery device into the patient'"'"'s nasal cavity until it reaches at least one of the patient'"'"'s maxillary sinus openings;

administering at least one effective dose of at least one therapeutic compound selected from the group consisting of an analgesic, an anesthetic, an anti-inflammatory compound, an antioxidant compound, an antiviral, an antibiotic, and bone morphogenic protein (BMP) via the delivery device through the at least one maxillary sinus opening, wherein the at least one effective dose comprises a volume of at least 0.3 milliliter;

depositing the at least one effective dose within the maxillary sinus; and

treating the structures innervated by the trigeminal nerve with the at least one therapeutic compound.

6. The method of claim 5, further comprising treating a patient with endodontic disease.

7. The method of claim 5, further comprising treating a patient with orthodontic pain.

8. The method of claim 5, further comprising treating a patient with temporomandibular disorder.

9. The method of claim 5, further comprising treating a patient in need of scaling, root planning and/or deep cleaning.

10. The method of claim 5, further comprising treating a patient in need of a root canal treatment.

11. The method of claim 5, further comprising treating a patient with rampant caries with quadrant dentistry.

12. The method of claim 5, further comprising treating a patient in need of full mouth reconstruction.

13. The method of claim 5, further comprising treating a patient before and/or while moving the patient'"'"'s teeth with braces.

14. A method to treat a patient'"'"'s anatomical structures innervated by the trigeminal nerve and in need thereof, comprising:

providing a delivery device adapted for insertion into the patient'"'"'s nasal cavity and operative connection with one of the patient'"'"'s maxillary sinus opening;

inserting the delivery device into the patient'"'"'s nasal cavity until it reaches at least one of the patient'"'"'s maxillary sinus opening;

administering at least one effective dose of at least one therapeutic compound selected from the group consisting of an analgesic, anesthetic, anti-inflammatory compound, an antioxidant compound, and an antiviral compound via the delivery device through the at least one maxillary sinus opening, wherein the at least one effective dose comprises a volume of at least 0.3 milliliter;

depositing the at least one effective dose within the maxillary sinus; and

treating the structures innervated by the trigeminal nerve with the at least one therapeutic compound, wherein the structures are selected from the group consisting of;

maxillary teeth, the nerve endings in the maxillary teeth, gums;

the nerve endings in the gums, vasculature innervated by the trigeminal nerve, temporomandibular joint, masseter muscle, lacrimal glands, parotid glands, submandibular glands, sublingual glands, meninges, skin of the forehead, tongue, maxilla, and mandible.

15. A method to treat the anatomical structure innervated by the trigeminal nerve in a patient in need thereof, comprising:

providing a delivery device adapted for insertion into the patient'"'"'s nasal cavity and operative connection with one of the patient'"'"'s maxillary sinus opening;

inserting the delivery device into the patient'"'"'s nasal cavity until it reaches at least one of the patient'"'"'s maxillary sinus opening;

administering at least one effective dose of at least one therapeutic substance selected from the group consisting of a vaccine, an antibiotic, an anesthetic, an analgesic, and an anti-inflammatory compound via the delivery device through the at least one maxillary sinus opening, wherein the at least one effective dose comprises a volume of at least 0.3 milliliter;

depositing the at least one effective dose within the maxillary sinus; and

treating the structures innervated by the trigeminal nerve with the therapeutic substance, the structures selected from the group consisting of;

nasal associated lymphatics and deep cervical lymph nodes, with the at least one therapeutic substance.

16. A method to treat a patient with Alzheimer'"'"'s disease, comprising:

providing a delivery device adapted for insertion into the patient'"'"'s nasal cavity and operative connection with one of the patient'"'"'s maxillary sinus opening;

inserting the delivery device into the patient'"'"'s nasal cavity until it reaches at least one of the patient'"'"'s maxillary sinus opening;

administering at least one effective dose of deferoxamine via the delivery device through the at least one maxillary sinus opening, wherein the at least one effective dose comprises a volume of at least 0.3 milliliter;

depositing the at least one effective dose within the maxillary sinus; and

ensuring the at least one effective dose of deferoxamine is delivered directly to the patient'"'"'s CNS from the maxillary sinus; and

treating the patient'"'"'s Alzheimer'"'"'s disease.

17. The method of claim 16, wherein the at least one effective dose of deferoxamine comprises 0.0001 to 1.0 mg/kg and has a volume of 0.3 to 15 ml.

18. The method of claim 16, wherein the at least one effective dose of deferoxamine comprises 0.0001 to 1.0 mg/kg and has a volume of 15 ml to 40 ml.

19. The method of claim 16, wherein the administration of deferoxamine inhibits spatial memory loss.

20. The method of claim 16, comprising administering the at least one effective dose of deferoxamine until the concentration of deferoxamine in the patient'"'"'s CNS is within the range of 0.01 nM to 50 μ

M.